A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer is a phase 3 interventional study registered as NCT02763566 by Eli Lilly and Company, with 463 participants enrolled, started 2016-12-05 and due to reach its primary completion in 2019-03-29. Interventions recorded: Abemaciclib, Anastrozole, Letrozole, Placebo and Fulvestrant. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Fulvestrant, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Shares Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Abemaciclib, Fulvestrant, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.